<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036372</url>
  </required_header>
  <id_info>
    <org_study_id>NL 41467.018.12</org_study_id>
    <nct_id>NCT02036372</nct_id>
  </id_info>
  <brief_title>Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus</brief_title>
  <acronym>PILGRIM</acronym>
  <official_title>PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of diabetes mellitus type II is increasing. More and more patients who need&#xD;
      surgery have diabetes mellitus type II. Despite an enormous amount of glucose lowering&#xD;
      protocols and the proven negative effects of hyperglycaemia. There is no evidence for the&#xD;
      optimal glucose lowering protocol.&#xD;
&#xD;
      This study investigates the optimal intraoperative treatment algorithm to lower glucose in&#xD;
      patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing&#xD;
      intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1&#xD;
      (liraglutide, LG) treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus is associated with poor outcome after surgery. The prevalence of diabetes&#xD;
      in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a&#xD;
      diabetes patient in the operating room on a daily basis. Multiple protocols for perioperative&#xD;
      glucose regulation have been developed, ranging from intravenous glucose-insulin-potassium&#xD;
      infusion to subcutaneous bolus regimens. Despite this abundance of published glucose lowering&#xD;
      protocols and the proven negative effects of intraoperative hyperglycaemia in diabetes, there&#xD;
      is no evidence regarding the optimal intraoperative glucose lowering treatment. Recently,&#xD;
      incretins have been introduced to lower blood glucose. The main hormone of the incretin&#xD;
      system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon&#xD;
      secretion in a glucose-dependent manner, resulting in low incidence of hypoglycaemia. This&#xD;
      study investigates for the first time the optimal intraoperative treatment algorithm to lower&#xD;
      glucose in patients with diabetes mellitus undergoing non-cardiac surgery.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      This study investigates the optimal intraoperative treatment algorithm to lower glucose in&#xD;
      patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing&#xD;
      intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1&#xD;
      (liraglutide, LG) treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median glucose</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>The difference in median glucose between the GIK + BR and LG group 1 hour after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Insulin administration</measure>
    <time_frame>1 day postoperative</time_frame>
    <description>The difference in insulin administration between the GIK + BR and LG group within 24 h after start of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median glucose</measure>
    <time_frame>4 hours and 1 day postoperative</time_frame>
    <description>The difference in median glucose between the GIK + BR and LG group 4 hours and 1 day after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>The difference in proportion of any postoperative complication within the first month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>From start treatment until the morning of day 1 postoperative</time_frame>
    <description>The occurrence of mild and severe hypoglycemia (glucose &lt;4.0 mmol/l and &lt;2.3 mmol/l, respectively) during and up to 24 h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypo- and hyperkalemia</measure>
    <time_frame>from start treatment until morning of day 1 postoperative</time_frame>
    <description>The occurrence of hypokalemia (&lt;3.5 mmol/l) and hyperkalemia (&gt;5.0 mmol/l) during and up to 24 h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>From start treatment until morning of day 1 postoperative</time_frame>
    <description>the difference in median glucose 1hr preoperative, 1, 4 hours postoperative, 1 day postoperative between the three groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes Mellitus Type II</condition>
  <arm_group>
    <arm_group_label>BR (bolus regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day before surgery: half evening dose long acting insulin&#xD;
Day of surgery:&#xD;
patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets&#xD;
patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets&#xD;
Measure blood glucose every 60 minutes, start 30 min prior to surgery&#xD;
Give bolus of insulin according to treatment algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day before surgery: half dose of long acting and mealtime insulin from start liraglutide&#xD;
Day of surgery: withhold own insulin, stop oral glucose lowering tablets&#xD;
Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.&#xD;
In case of nausea graded higher than minimal, the patient will be excluded from the study&#xD;
Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.&#xD;
Measure glucose every 60 minutes, start 30 min prior to surgery&#xD;
Adjust according to bolus algorithm of BR group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIK (glucose -insulin - potassium) infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day before surgery: half evening dose long acting insulin&#xD;
Day of surgery: stop oral glucose lowering tablets and withhold own insulin.&#xD;
GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.&#xD;
Calculate the insulin amount in the GIK infusion according to the formula:&#xD;
I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg&#xD;
Measure blood glucose every 60 minutes, start 30 min prior to surgery&#xD;
Adjust glucose &gt; 8 mmol/l according to treatment algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin bolus</intervention_name>
    <arm_group_label>BR (bolus regimen)</arm_group_label>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <other_name>novorapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIK infusion</intervention_name>
    <description>continuous infusion</description>
    <arm_group_label>GIK (glucose -insulin - potassium) infusion</arm_group_label>
    <other_name>glucose, insulin, potassium infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  known diabetes mellitus type II for &gt; 3 months&#xD;
&#xD;
          -  aged 18-75 years&#xD;
&#xD;
          -  scheduled for elective non-cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Daily insulin dosage of &gt; 1 IU/kg body weight&#xD;
&#xD;
          -  Oral corticosteroid use&#xD;
&#xD;
          -  Planned for day-care (ambulant) surgery&#xD;
&#xD;
          -  Planned ICU stay post-operatively&#xD;
&#xD;
          -  Planned bowel surgery&#xD;
&#xD;
          -  History of chronic pancreatitis or idiopathic acute pancreatitis&#xD;
&#xD;
          -  Impaired renal function defined as serum-creatinine ≥ 133 μmol/L for males and ≥ 115&#xD;
             μmol/L for females&#xD;
&#xD;
          -  Females of child bearing potential who are pregnant, breast-feeding or intend to&#xD;
             become pregnant or are not using adequate contraceptive methods (adequate&#xD;
             contraceptive measures as required by local law or practice)&#xD;
&#xD;
          -  Known or suspected allergy to trial product(s) or related products&#xD;
&#xD;
          -  Any condition that the local investigator feels would interfere with trial&#xD;
             participation or the evaluation of results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Preckel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre - AMC-UvA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>Please Select</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://diapedia.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>B Preckel</investigator_full_name>
    <investigator_title>Prof dr B Preckel, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>perioperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

